Free Trial

AbbVie (ABBV) Competitors

$155.06
-2.00 (-1.27%)
(As of 10:15 AM ET)

ABBV vs. MRK, JNJ, PFE, BMY, ZTS, MRNA, IDXX, IQV, BNTX, and ILMN

Should you be buying AbbVie stock or one of its competitors? The main competitors of AbbVie include Merck & Co., Inc. (MRK), Johnson & Johnson (JNJ), Pfizer (PFE), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Moderna (MRNA), IDEXX Laboratories (IDXX), IQVIA (IQV), BioNTech (BNTX), and Illumina (ILMN). These companies are all part of the "medical" sector.

AbbVie vs.

Merck & Co., Inc. (NYSE:MRK) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, community ranking, earnings, valuation and risk.

76.1% of Merck & Co., Inc. shares are owned by institutional investors. Comparatively, 70.2% of AbbVie shares are owned by institutional investors. 0.1% of Merck & Co., Inc. shares are owned by insiders. Comparatively, 0.3% of AbbVie shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

AbbVie has a net margin of 11.02% compared to AbbVie's net margin of 3.76%. Merck & Co., Inc.'s return on equity of 179.47% beat AbbVie's return on equity.

Company Net Margins Return on Equity Return on Assets
Merck & Co., Inc.3.76% 14.05% 5.24%
AbbVie 11.02%179.47%14.05%

In the previous week, AbbVie had 10 more articles in the media than Merck & Co., Inc.. MarketBeat recorded 23 mentions for AbbVie and 13 mentions for Merck & Co., Inc.. AbbVie's average media sentiment score of 1.16 beat Merck & Co., Inc.'s score of 0.84 indicating that Merck & Co., Inc. is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Merck & Co., Inc.
13 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
AbbVie
13 Very Positive mention(s)
2 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

AbbVie has lower revenue, but higher earnings than Merck & Co., Inc.. AbbVie is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Merck & Co., Inc.$60.12B5.46$365M$0.90143.88
AbbVie$54.40B5.10$4.86B$3.3746.61

Merck & Co., Inc. pays an annual dividend of $3.08 per share and has a dividend yield of 2.4%. AbbVie pays an annual dividend of $6.20 per share and has a dividend yield of 3.9%. Merck & Co., Inc. pays out 342.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. AbbVie pays out 184.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Merck & Co., Inc. has raised its dividend for 13 consecutive years and AbbVie has raised its dividend for 52 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Merck & Co., Inc. has a beta of 0.39, suggesting that its share price is 61% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500.

AbbVie received 335 more outperform votes than Merck & Co., Inc. when rated by MarketBeat users. Likewise, 73.10% of users gave AbbVie an outperform vote while only 66.97% of users gave Merck & Co., Inc. an outperform vote.

CompanyUnderperformOutperform
Merck & Co., Inc.Outperform Votes
967
66.97%
Underperform Votes
477
33.03%
AbbVieOutperform Votes
1302
73.10%
Underperform Votes
479
26.90%

Merck & Co., Inc. currently has a consensus target price of $131.33, indicating a potential upside of 1.42%. AbbVie has a consensus target price of $176.14, indicating a potential upside of 12.15%. Given Merck & Co., Inc.'s stronger consensus rating and higher possible upside, analysts plainly believe AbbVie is more favorable than Merck & Co., Inc..

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Merck & Co., Inc.
1 Sell rating(s)
3 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.58
AbbVie
0 Sell rating(s)
3 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.79

Summary

AbbVie beats Merck & Co., Inc. on 16 of the 21 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABBV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ABBV vs. The Competition

MetricAbbViePharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$277.35B$6.50B$5.00B$17.80B
Dividend Yield3.92%2.79%2.82%3.53%
P/E Ratio46.6122.12160.2525.71
Price / Sales5.10239.342,538.6311.56
Price / Cash9.9320.9632.8915.70
Price / Book27.175.894.955.09
Net Income$4.86B$119.85M$103.75M$972.52M
7 Day Performance-4.59%-3.08%-1.32%-1.58%
1 Month Performance-1.60%1.00%3.38%4.59%
1 Year Performance14.18%-4.61%5.41%23.69%

AbbVie Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MRK
Merck & Co., Inc.
4.5029 of 5 stars
$130.78
-0.2%
$131.33
+0.4%
+16.6%$331.24B$60.12B145.3172,000Positive News
JNJ
Johnson & Johnson
4.7778 of 5 stars
$151.25
0.0%
$175.86
+16.3%
-4.8%$364.01B$85.16B9.43131,900
PFE
Pfizer
4.7572 of 5 stars
$28.56
+0.1%
$35.86
+25.6%
-23.2%$161.67B$54.89B-475.9288,000
BMY
Bristol-Myers Squibb
4.9901 of 5 stars
$42.29
-2.5%
$60.00
+41.9%
-35.4%$85.73B$45.01B-13.6434,100Analyst Revision
ZTS
Zoetis
4.7111 of 5 stars
$172.79
-0.9%
$211.75
+22.5%
+3.2%$78.84B$8.54B33.2914,100Dividend Announcement
Analyst Revision
MRNA
Moderna
3.3632 of 5 stars
$143.69
+1.9%
$126.46
-12.0%
+32.0%$55.07B$6.85B-9.175,600Analyst Revision
IDXX
IDEXX Laboratories
4.4478 of 5 stars
$518.44
-2.2%
$580.38
+11.9%
+10.1%$42.82B$3.66B50.1911,000
IQV
IQVIA
4.2858 of 5 stars
$229.38
-0.3%
$257.57
+12.3%
+15.1%$41.79B$14.98B31.3487,000Analyst Revision
BNTX
BioNTech
0.9618 of 5 stars
$92.07
-0.4%
$111.70
+21.3%
-7.9%$21.89B$4.13B184.146,133
ILMN
Illumina
4.8535 of 5 stars
$107.61
-0.8%
$164.65
+53.0%
-45.6%$17.14B$4.50B-13.209,300

Related Companies and Tools

This page (NYSE:ABBV) was last updated on 5/28/2024 by MarketBeat.com Staff

From Our Partners